Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1882 1
1956 1
1957 1
1964 1
1965 3
1966 1
1968 3
1969 4
1970 1
1971 3
1972 5
1973 3
1974 2
1975 5
1976 13
1977 19
1978 11
1979 10
1980 15
1981 17
1982 19
1983 26
1984 38
1985 31
1986 38
1987 39
1988 47
1989 67
1990 74
1991 78
1992 101
1993 129
1994 156
1995 178
1996 187
1997 172
1998 161
1999 152
2000 153
2001 141
2002 153
2003 175
2004 185
2005 215
2006 228
2007 284
2008 265
2009 268
2010 325
2011 330
2012 364
2013 390
2014 381
2015 439
2016 410
2017 456
2018 493
2019 524
2020 612
2021 687
2022 338
Text availability
Article attribute
Article type
Publication date

Search Results

8,658 results
Results by year
Filters applied: . Clear all The following term was not found in PubMed: Hojsak1
Page 1
Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management.
Sawamoto K, Álvarez González JV, Piechnik M, Otero FJ, Couce ML, Suzuki Y, Tomatsu S. Sawamoto K, et al. Int J Mol Sci. 2020 Feb 23;21(4):1517. doi: 10.3390/ijms21041517. Int J Mol Sci. 2020. PMID: 32102177 Free PMC article. Review.
Mucopolysaccharidosis type IVA (MPS IVA, or Morquio syndrome type A) is an inherited metabolic lysosomal disease caused by the deficiency of the N-acetylglucosamine-6-sulfate sulfatase enzyme. ...GAG accumulation in these lesions leads to unique skeletal dysplasia i …
Mucopolysaccharidosis type IVA (MPS IVA, or Morquio syndrome type A) is an inherited metabolic lysosomal disease caused by the …
Mucopolysaccharidosis Type IVA.
Regier DS, Oetgen M, Tanpaiboon P. Regier DS, et al. 2013 Jul 11 [updated 2021 Jun 17]. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022. 2013 Jul 11 [updated 2021 Jun 17]. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022. PMID: 23844448 Free Books & Documents. Review.
CLINICAL CHARACTERISTICS: The phenotypic spectrum of mucopolysaccharidosis IVA (MPS IVA) is a continuum that ranges from a severe and rapidly progressive early-onset form to a slowly progressive later-onset form. ...Compression of the spinal cord is a common complic …
CLINICAL CHARACTERISTICS: The phenotypic spectrum of mucopolysaccharidosis IVA (MPS IVA) is a continuum that ranges from a sev …
Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review.
Dagenais RVE, Su VCH, Quon BS. Dagenais RVE, et al. J Clin Med. 2020 Dec 23;10(1):23. doi: 10.3390/jcm10010023. J Clin Med. 2020. PMID: 33374882 Free PMC article. Review.
The objectives of this systematic review were to summarize real-world AEs reported for market-available CFTR modulators (i.e., ivacaftor (IVA), lumacaftor/ivacaftor (LUM/IVA), tezacaftor/ivacaftor (TEZ/IVA), and elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IV …
The objectives of this systematic review were to summarize real-world AEs reported for market-available CFTR modulators (i.e., ivacaftor ( …
Diagnosing mucopolysaccharidosis IVA.
Wood TC, Harvey K, Beck M, Burin MG, Chien YH, Church HJ, D'Almeida V, van Diggelen OP, Fietz M, Giugliani R, Harmatz P, Hawley SM, Hwu WL, Ketteridge D, Lukacs Z, Miller N, Pasquali M, Schenone A, Thompson JN, Tylee K, Yu C, Hendriksz CJ. Wood TC, et al. J Inherit Metab Dis. 2013 Mar;36(2):293-307. doi: 10.1007/s10545-013-9587-1. Epub 2013 Feb 1. J Inherit Metab Dis. 2013. PMID: 23371450 Free PMC article.
Mucopolysaccharidosis IVA (MPS IVA; Morquio A syndrome) is an autosomal recessive lysosomal storage disorder resulting from a deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS) activity. ...Urinary glycosaminoglycan analysis is particularly problematic …
Mucopolysaccharidosis IVA (MPS IVA; Morquio A syndrome) is an autosomal recessive lysosomal storage disorder resulting from a …
Insights into the diversification of subclade IVa bHLH transcription factors in Fabaceae.
Suzuki H, Seki H, Muranaka T. Suzuki H, et al. BMC Plant Biol. 2021 Feb 23;21(1):109. doi: 10.1186/s12870-021-02887-w. BMC Plant Biol. 2021. PMID: 33622255 Free PMC article.
We aimed to systematically elucidate the diversification of this subclade and obtain insights into the evolutionary history of saponin biosynthesis regulation in Fabaceae. RESULTS: In this study, we collected sequences of subclade IVa bHLH proteins from 40 species, includi …
We aimed to systematically elucidate the diversification of this subclade and obtain insights into the evolutionary history of saponin biosy …
Biopharmaceutics classification and intestinal absorption of chikusetsusaponin IVa.
Zhang W, Liu H, Liu C. Zhang W, et al. Biopharm Drug Dispos. 2019 Sep;40(8):276-281. doi: 10.1002/bdd.2200. Epub 2019 Jul 28. Biopharm Drug Dispos. 2019. PMID: 31294470
The equilibrium solubility of CHS-IVa was determined by the shaker method. The absorption mechanism of CHS-IVa in the intestine was studied by comparing the P(eff) of different concentrations of CHS-IVa. ...The permeability of CHS-IVa was investigated …
The equilibrium solubility of CHS-IVa was determined by the shaker method. The absorption mechanism of CHS-IVa in the intestin …
Ethnomedicinal use, phytochemistry, pharmacology, and toxicology of Ajuga iva (L.,) schreb.
Bouyahya A, El Omari N, Elmenyiy N, Guaouguaou FE, Balahbib A, El-Shazly M, Chamkhi I. Bouyahya A, et al. J Ethnopharmacol. 2020 Aug 10;258:112875. doi: 10.1016/j.jep.2020.112875. Epub 2020 May 6. J Ethnopharmacol. 2020. PMID: 32387464 Review.
ETHNOPHARMACOLOGICAL RELEVANCE: Ajuga iva (L.,) Schreb (A. iva). is a medicinal plant commonly used in Africa to treat several diseases such as diabetes, rheumatism, allergy, cancer, renal, metabolic disorders, cardiovascular disorders, digestive, and respiratory di …
ETHNOPHARMACOLOGICAL RELEVANCE: Ajuga iva (L.,) Schreb (A. iva). is a medicinal plant commonly used in Africa to treat several …
Elosulfase alfa.
Haddley K. Haddley K. Drugs Today (Barc). 2014 Jul;50(7):475-83. doi: 10.1358/dot.2014.50.7.2177904. Drugs Today (Barc). 2014. PMID: 25101330 Review.
Mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome, is an inherited, lysosomal storage disorder caused by genetic mutations in N-acetylgalactosamine-6-sulfatase (GALNS) enzyme gene. ...BioMarin Pharmaceutical developed elosulfase alfa, a reco …
Mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome, is an inherited, lysosomal storage disorder caused …
Inhibition of chikusetsusaponin IVa on inflammatory responses in RAW264.7 cell line via MAPK pathway.
Xu G, Lei H, Yuan Q, Chen H, Su J. Xu G, et al. Z Naturforsch C J Biosci. 2020 Sep 28;76(3-4):103-110. doi: 10.1515/znc-2019-0107. Print 2021 Mar 26. Z Naturforsch C J Biosci. 2020. PMID: 32986614
Chikusetsusaponin IVa (CHS-IVa), a saponin from herb Panacis japonicas, possesses extensive biological activities. However, the roles and underlying mechanisms of CHS-IVa on inflammation have not been fully clarified in the setting of murine macrophages. ...
Chikusetsusaponin IVa (CHS-IVa), a saponin from herb Panacis japonicas, possesses extensive biological activities. However, th …
Aristolochic acid IVa forms DNA adducts in vitro but is non-genotoxic in vivo.
Wan J, Chen R, Yang Z, Xi J, Cao Y, Chen Y, Zhang X, Luan Y. Wan J, et al. Arch Toxicol. 2021 Aug;95(8):2839-2850. doi: 10.1007/s00204-021-03077-1. Epub 2021 Jul 5. Arch Toxicol. 2021. PMID: 34223934
AA IVa reacted with 2'-deoxyadenosine (dA) and 2'-deoxyguanosine (dG) to form three dA and five dG adducts as identified by high-resolution mass spectrometry, among which two dA and three dG adducts were detected in reactions of AA IVa with calf thymus DNA (CT DNA). …
AA IVa reacted with 2'-deoxyadenosine (dA) and 2'-deoxyguanosine (dG) to form three dA and five dG adducts as identified by high-reso …
8,658 results